Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

April 13, 2021; 96 (15 Supplement) Tuesday, April 20

Efficacy and Safety Results of the Avalglucosidase alfa Phase 3 COMET Trial in Late-Onset Pompe Disease Patients (4195)

Hani Kushlaf, Shahram Attarian, Joao Lindolfo Borges, Francoise Bouhour, Yin-Hsiu Chien, Young-Chul Choi, Paula Clemens, John Day, Jordi Diaz-Manera, Sevim Erdem-Ozdamar, Ozlem Goker-Alpan, Sergey Illarioshkin, Priya Kishnani, Anna Kostera-Pruszczyk, Shafeeq Ladha, Tahseen Mozaffar, Mark Roberts, Volker Straub, Antonio Toscano, Ans van der Ploeg, Kristina An Haack, Christopher Hug, Olivier Huynh-Ba, Tianyue Zhou, Judith Johnson, Mazen Dimachkie, Benedikt Schoser
First published April 13, 2021,
Hani Kushlaf
1Department of Neurology & Rehabilitation Medicine and Department of Pathology & Laboratory Medicine, University of Cincinnati
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shahram Attarian
2Referral Centre for Neuromuscular Diseases and ALS, Hôpital La Timone
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joao Lindolfo Borges
3Clinical Research Center of Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francoise Bouhour
4Pierre Wertheimer Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yin-Hsiu Chien
5Department of Medical Genetics and Pediatrics, National Taiwan University Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Young-Chul Choi
6Gangnam Severance Hospital, Yonsei University, College of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paula Clemens
7Univ of Pittsburgh/Dept of Neurology
8Department of Veterans Affairs Medical Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Day
9Stanford University School of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jordi Diaz-Manera
10John Walton Muscular Dystrophy Research Center, Newcastle University
11Neuromuscular Diseases Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau
12Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sevim Erdem-Ozdamar
13Hacettepe University Department of Neurology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ozlem Goker-Alpan
14O and O Alpan LLC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sergey Illarioshkin
15Research Center of Neurology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Priya Kishnani
16Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Kostera-Pruszczyk
17Department of Neurology, Medical University of Warsaw
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shafeeq Ladha
18Barrow Neurological Institute
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tahseen Mozaffar
19Department of Neurology, University of California, Irvine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Roberts
20Salford Royal NHS Foundation Trust
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Volker Straub
21Newcastle University John Walton Muscular Dystrophy Research Centre, Newcastle Hospitals NHS Foundation Trust
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonio Toscano
22Neurology and Neuromuscular Diseases Unit, Department of Clinical and Experimental Medicine, University of Messina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ans van der Ploeg
23Center for Lysosomal and Metabolic Diseases, Erasmus MC, University Medical Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kristina An Haack
24Sanofi Genzyme
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Hug
24Sanofi Genzyme
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olivier Huynh-Ba
24Sanofi Genzyme
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tianyue Zhou
24Sanofi Genzyme
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Judith Johnson
24Sanofi Genzyme
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mazen Dimachkie
25University of Kansas Medical Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benedikt Schoser
26Department of Neurology, Friedrich-Baur-Institute, Klinikum München
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Efficacy and Safety Results of the Avalglucosidase alfa Phase 3 COMET Trial in Late-Onset Pompe Disease Patients (4195)
Hani Kushlaf, Shahram Attarian, Joao Lindolfo Borges, Francoise Bouhour, Yin-Hsiu Chien, Young-Chul Choi, Paula Clemens, John Day, Jordi Diaz-Manera, Sevim Erdem-Ozdamar, Ozlem Goker-Alpan, Sergey Illarioshkin, Priya Kishnani, Anna Kostera-Pruszczyk, Shafeeq Ladha, Tahseen Mozaffar, Mark Roberts, Volker Straub, Antonio Toscano, Ans van der Ploeg, Kristina An Haack, Christopher Hug, Olivier Huynh-Ba, Tianyue Zhou, Judith Johnson, Mazen Dimachkie, Benedikt Schoser
Neurology Apr 2021, 96 (15 Supplement) 4195;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: Results (Baseline to Week 49) of the double-blinded Phase 3 COMET trial (NCT02782741/Sanofi Genzyme) comparing avalglucosidase alfa (n=51) and alglucosidase alfa (n=49) in treatment-naïve patients with late-onset Pompe disease (LOPD) are reported.

Background: Avalglucosidase alfa is a recombinant human GAA enzyme replacement therapy specifically designed for enhanced M6P-receptor targeting and enzyme uptake aimed at increased glycogen clearance and improvement of clinical efficacy as compared to alglucosidase alfa.

Design/Methods: The primary objective was to determine the effect of avalglucosidase alfa on respiratory muscle function, measured by upright forced vital capacity (FVC) %predicted. Secondary/other objectives include the effect of avalglucosidase alfa on functional endurance, inspiratory and expiratory muscle strength, lower and upper extremity muscle strength, motor function, and health-related quality of life, and safety.

Results: Treatment with avalglucosidase alfa resulted in greater improvements in upright FVC %predicted at all timepoints and a 2.43% greater increase in FVC %predicted compared to alglucosidase alfa at Week 49. The primary study objective, achieving statistical non-inferiority, was met (p=0.0074) and testing for superiority was borderline significant (p=0.0626). Avalglucosidase alfa treatment resulted in greater improvements in the 6-Minute Walk Test (6MWT) (meters and %predicted), with 30.01-m and 4.71% greater increases, respectively. Similarly, positive results for avalglucosidase alfa were seen for all secondary and other efficacy endpoints. Treatment-emergent adverse events (AEs) were reported in 86.3% of avalglucosidase alfa-treated and 91.8% of alglucosidase alfa-treated participants. Five participants withdrew, four due to AEs, all in the alglucosidase alfa arm. Serious AEs were reported in 8 avalglucosidase alfa-treated and 12 alglucosidase alfa-treated participants. IgG antidrug antibody responses were similar in both groups. High titers and neutralizing antibodies were more common for alglucosidase alfa.

Conclusions: These results demonstrate substantial improvements in clinically meaningful outcome measures as well as a more favorable safety profile in patients with LOPD treated with avalglucosidase alfa compared to alglucosidase alfa.

Disclosure: Dr. Kushlaf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Kushlaf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Kushlaf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Genzyme. Dr. Kushlaf has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Genzyme. Dr. Kushlaf has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Akcea. Dr. Kushlaf has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Catalyst Pharmaceuticals . Prof. Attarian has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SANOFI, Pfizer LFB, Alnylam Biogen . Prof. Attarian has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for SANOFI, Biogen. The institution of Prof. Attarian has received research support from National Institut of Health . Joao Lindolfo Borges has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eurofarma. Francoise Bohour has nothing to disclose. Yin-Hsiu Chien has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi Genzyme. Yin-Hsiu Chien has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Yin-Hsiu Chien has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Yin-Hsiu Chien has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi Genzyme. Yin-Hsiu Chien has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Avexis/Norvatis. Yin-Hsiu Chien has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. The institution of Yin-Hsiu Chien has received research support from Biogen. The institution of Yin-Hsiu Chien has received research support from Sanofi Genzyme. Young-Chul Choi has nothing to disclose. Dr. Clemens has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Spark Therapeutics. Dr. Clemens has received personal compensation in the range of $500-$4,999 for serving as a Consultant for F. Hoffman-La Roche. The institution of Dr. Clemens has received research support from NS Pharma. The institution of Dr. Clemens has received research support from ReveraGen. Dr. Day has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Affinia Therapeutics. Dr. Day has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis Gene Therapy. Dr. Day has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Day has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech. Dr. Day has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Day has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Scholar Rock. Dr. Day has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Avidity. Dr. Day has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Muscular Dystrophy Association. The institution of Dr. Day has received research support from Audentes. The institution of Dr. Day has received research support from Novartis Gene Therapy. The institution of Dr. Day has received research support from Biogen. The institution of Dr. Day has received research support from Cytokinetics. The institution of Dr. Day has received research support from Roche/Genentech. The institution of Dr. Day has received research support from Sanofi/Genzyme. The institution of Dr. Day has received research support from Sarepta. The institution of Dr. Day has received research support from Scholar Rock. Dr. Day has received intellectual property interests from a discovery or technology relating to health care. Jordi Diaz-Manera has nothing to disclose. Sevim Erdem-Ozdamar has nothing to disclose. The institution of Ozlem Alpan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi-Genzyme . The institution of Ozlem Alpan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Ozlem Alpan has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Prevail . Ozlem Alpan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi-Genzyme . The institution of Ozlem Alpan has received research support from Sanofi genzyme . The institution of Ozlem Alpan has received research support from Shire HGT . The institution of Ozlem Alpan has received research support from Amicus. Ozlem Alpan has received intellectual property interests from a discovery or technology relating to health care. Sergey Illarioshkin has nothing to disclose. Priya Kishnani, MD has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi/Genzyme. Priya Kishnani, MD has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi/Genzyme. Priya Kishnani, MD has received research support from Sanofi/Genzyme. Anna Kostera-Pruszczyk has nothing to disclose. Dr. Ladha has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Ladha has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Ladha has received research support from Biogen. Dr. Mozaffar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbvie. Dr. Mozaffar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alexion Pharmaceuticals. Dr. Mozaffar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Argenx. Dr. Mozaffar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Mozaffar has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amicus. Dr. Mozaffar has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Modis Therapeutics. Dr. Mozaffar has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acceleron. Dr. Mozaffar has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for CSL. Dr. Mozaffar has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi-Genzyme. Dr. Mozaffar has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Neuromuscular Disease Foundation. The institution of Dr. Mozaffar has received research support from NIH. The institution of Dr. Mozaffar has received research support from Muscular Dystrophy Association. The institution of Dr. Mozaffar has received research support from The Myositis Association. The institution of Dr. Mozaffar has received research support from Sanofi-Genzyme. The institution of Dr. Mozaffar has received research support from Orphazyme. The institution of Dr. Mozaffar has received research support from Argenx. The institution of Dr. Mozaffar has received research support from Bristol-Myers Squibb. The institution of Dr. Mozaffar has received research support from Valerion Therapeutics. The institution of Dr. Mozaffar has received research support from Momenta. The institution of Dr. Mozaffar has received research support from Amicus Therapeutics. The institution of Dr. Mozaffar has received research support from Spark Therapeutics. The institution of Dr. Mozaffar has received research support from Audentes Therapeutics. The institution of Dr. Mozaffar has received research support from Cartesian. Dr. Mozaffar has received personal compensation in the range of $500-$4,999 for serving as a Study Section Member with NIH. Dr. Mozaffar has received personal compensation in the range of $500-$4,999 for serving as a Director, Virtual Course on Inclusion Body Myositis with Muscular Dystrophy Association. Dr. Mozaffar has received personal compensation in the range of $0-$499 for serving as a Speaker with California Neurological Association. Dr. Mozaffar has a non-compensated relationship as a Director, Annual Muscle Course with American Academy of Neurology that is relevant to AAN interests or activities. Mark Roberts has nothing to disclose. Volker Straub has nothing to disclose. Dr. Toscano has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Genzyme. The institution of Ans Van Der Ploeg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi Genzyme . The institution of Ans Van Der Ploeg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amicus. The institution of Ans Van Der Ploeg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Spark Therapeutics . The institution of Ans Van Der Ploeg has received research support from Sanofi Genzyme. Kristina an Haack has received personal compensation for serving as an employee of Sanofi. An immediate family member of Kristina an Haack has received personal compensation for serving as an employee of Sanofi. Christopher Hug has received personal compensation for serving as an employee of Sanofi. Christopher Hug has received stock or an ownership interest from Sanofi. The institution of an immediate family member of Christopher Hug has received research support from NIH. Olivier Huynh-Ba has received personal compensation for serving as an employee of Sanofi. TIANYUE ZHOU has received personal compensation for serving as an employee of Sanofi. TIANYUE ZHOU has received stock or an ownership interest from Sanofi. Judith Johnson has received personal compensation for serving as an employee of Sanofi. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EcoR1 Capital, LLC. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cello Health BioConsulting, previously Defined Health. Dr. Dimachkie has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. Dr. Dimachkie has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for CSL Behring. Dr. Dimachkie has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Octapharma. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ArgenX. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Spark Therapeutics. Dr. Dimachkie has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for RAF-5. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Houston NeuroCare. Dr. Dimachkie has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Shire. Dr. Dimachkie has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Catalyst. Dr. Dimachkie has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for CSL Behring. The institution of Dr. Dimachkie has received research support from CSL Behring. The institution of Dr. Dimachkie has received research support from Orphazyme. Dr. Dimachkie has received intellectual property interests from a discovery or technology relating to health care. Benedikt Schoser, 18260 has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi Genzyme. Benedikt Schoser, 18260 has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofo Genzyme. Benedikt Schoser, 18260 has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Nexien. Benedikt Schoser, 18260 has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amicus. Benedikt Schoser, 18260 has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Audentes. Benedikt Schoser, 18260 has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB. Benedikt Schoser, 18260 has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Kedrion.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study

Dr. Robert Shapiro and Dr. Amynah Pradhan

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 100 (6)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise